Mucera

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mucera

Property Description
Active Ingredient Ambroxol (Ambroxol Hydrochloride)
Form Tablets, Syrup, Drops, Solutions (Oral, Inhalation, Parenteral)
Pharmacological Class Mucoactive agent (Mucolytic and Secretolytic)
Common Use Facilitates clearance of thick, tenacious bronchial secretions
Origin Synthetic compound (derivative of Bromhexine)

What is the Active Ingredient and Pharmacological Class of Mucera?

Mucera is a pharmaceutical preparation defined by its single active component, Ambroxol (Ambroxol Hydrochloride). This substance is a synthetic compound, specifically the N-desmethyl metabolite derived from the related expectorant Bromhexine. Pharmacologically, Ambroxol is classified as a mucoactive agent, which is a broad category for drugs that alter the properties of respiratory mucus. This classification relates to its function in breaking down complex mucus structures.

Its function places it primarily in the classes of a mucolytic agent and a secretolytic agent, designated by the Anatomical Therapeutic Chemical (ATC) code R05CB06. The drug's mechanism also includes a secondary effect due to the inhibition of neuronal sodium channels, which can provide a distinct, localized soothing sensation in the throat.

What Types of Preparations is Mucera Available In?

Mucera is manufactured in various dosage forms to accommodate patient needs, including oral preparations such as tablets, syrup, and drops. The medication is also formulated as specialized solutions for inhalation and, in certain clinical settings, as sterile parenteral solutions for intravenous or intramuscular use, reflecting its versatility in administration across different age groups. The high-level composition of these products involves the active Ambroxol component embedded in a solid matrix of excipients for tablets or dispersed in an aqueous or hydroalcoholic base for its liquid preparations.

What is the General Purpose of Mucera?

The general purpose of Mucera is to facilitate airway secretion clearance by normalizing the physical properties of mucus. Its core function involves thinning the consistency of thick, tenacious phlegm, reducing its viscosity and making it easier to mobilize from the respiratory tract. This action helps to support the body’s natural defense mechanisms by enhancing mucociliary transport. The overall benefit is to provide general relief from the discomfort and obstruction, such as chest congestion or difficulty expectorating, caused by excessive or abnormally thick bronchial secretions.

Regulatory References

  1. EMA referral: Ambroxol- and bromhexine-containing medicines

What side effects are possible with Mucera?

Possible side effects and safety information

Official regulatory documents classify the potential adverse reactions of Ambroxol (the active ingredient in Mucera) by frequency and the body system affected, providing a structured profile of known risks.

Adverse reactions are grouped by frequency:

  • Common (ge 1/100 to < 1/10): Nausea, taste disturbance (dysgeusia), and numbness in the mouth or throat (oral and pharyngeal hypoesthesia).
  • Uncommon (ge 1/1000 to < 1/100): Vomiting, diarrhoea, abdominal pain, indigestion (dyspepsia), and dry mouth.
  • Rare (ge 1/10000 to < 1/1000): Hypersensitivity reactions, rash, and hives (urticaria).

The effects primarily occur in Gastrointestinal disorders and the Nervous system. Rare, but serious, reactions documented in post-marketing reports include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, as well as Anaphylactic reactions including anaphylactic shock. The frequency of these serious events is classified as Not Known (cannot be estimated from available data) [Source 1.5, 2.3].

Official safety statements indicate caution is required for specific populations. The medicine is not recommended for use during the first trimester of pregnancy or for women who are breastfeeding. Safety notes also advise caution in individuals with a history of peptic ulcers or severe renal or hepatic impairment, where accumulation of the drug's metabolites may be expected [Source 1.1, 3.3]. Concomitant use with antitussive agents (cough suppressants) is discouraged, as it may lead to the obstruction of airways with liquefied mucus due to the inhibited cough reflex [Source 1.2, 1.3].

Overdose and Emergency Response

Official Documented Overdose Manifestations

Regulatory documents define the typical overdose presentation for Mucera (Ambroxol) as generally mild, consistent with an extension of known undesirable effects. No severe signs of intoxication are reported in routine human cases.

The most common documented manifestations include symptoms affecting the gastrointestinal and nervous systems, specifically short-term restlessness or agitation, along with diarrhea, nausea, vomiting, and abdominal pain.

Severe Risk and Emergency Action

While typical overdose is mild, in scenarios of extreme overdosage, preclinical data anticipates potential severe systemic effects, including hypotension (a significant drop in blood pressure) and excessive saliva secretion.

Regulatory labeling requires individuals to consult a doctor or emergency room immediately upon any suspicion of having taken more than the prescribed dosage. This is mandated to ensure necessary symptomatic treatment and supportive care, as no specific antidote is known.

Treatment and Special Considerations

Treatment for overdosage is required to be mainly symptomatic. Acute procedural measures, such as gastric lavage, are not generally indicated but may be considered by medical professionals only in cases of acute, very high ingestion. Patient observation should be ensured. Additionally, patients with severe renal insufficiency or severe liver disease should be observed closely due to the expected accumulation of hepatic metabolites.

Therapeutic Uses of Mucera

What Mucera Treats: Main Uses and Benefits

The following information focuses on the therapeutic use of Mucera for symptomatic relief. The medication is relevant for easing symptoms that interfere with daily functioning, specifically those linked to highly viscous secretions.

The medication is commonly used across conditions presenting with acute episodes and recurrent manifestations, including acute bronchitis, forms of Chronic Obstructive Pulmonary Disease (COPD), and other conditions where excessive, tenacious phlegm is present. It assists with maintaining functional stability, which supports the patient during difficult episodes by easing distress when an inefficient productive cough fails to clear the airways. The medication also offers symptomatic relief for localized discomfort, such as an acute sore throat.

“It contributes to easing the overall symptom load and discomfort during periods when symptoms may intensify temporarily.”

Quick Fact: Relief for Inefficient Cough One important benefit is applied in addressing symptoms related to physical discomfort, such as chest congestion and difficulty in expectorating thick secretions, which contributes to improved comfort during symptomatic periods.

Regulatory References

  1. European Medicines Agency assessment of Ambroxol

Eligibility and Restrictions for Use

Official Eligibility and Restriction Status

Mucera (Ambroxol) eligibility is strictly defined by regulatory documents, focusing on populations for whom use is prohibited, restricted, or requires special consideration.

Population Group Eligibility Status
Hypersensitivity Contraindicated (to Ambroxol, Bromhexine, or excipients)
First Trimester Pregnancy Not Recommended (Advisable to avoid use)
Breastfeeding Mothers Not Recommended (Excreted in breast milk)
Severe Renal/Hepatic Impairment Conditional Use (Requires medical supervision; dose may be reduced)
Peptic/Duodenal Ulcers (History) Caution Required (Due to potential mucosal effects)
Children under 2 years Not Recommended/Contraindicated (Formulation dependent; requires medical advice)
Adults and Adolescents (>12 yrs) Allowed (Standard eligible population)

Use is absolutely contraindicated for patients with known hypersensitivity or rare hereditary conditions that cause intolerance to specific excipients, such as lactose or sorbitol, present in certain formulations. The medicine should be used only under medical supervision in cases of severe kidney or liver impairment, as these conditions may reduce the clearance of the substance, necessitating dose adjustments. Though generally permitted in later pregnancy, the use of Mucera is not recommended during the first trimester or while breastfeeding, as a precautionary measure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Interaction Profile

The official interaction profile for Mucera (Ambroxol) is defined by one mandatory pharmacodynamic restriction and specific pharmacokinetic effects on co-administered substances, as documented in government regulatory labeling.

Category Documented Interaction Regulatory Restriction
Pharmacodynamic Cough Suppressants (Antitussives) Co-administration is not recommended due to the risk of accumulation of secretions.
Pharmacokinetic Antibiotics (Amoxicillin, Cefuroxime, Erythromycin, Doxycycline) Co-administration leads to an increase in the concentrations of these antibiotics in lung tissue and bronchial secretions.

Population-Specific Considerations

The product labeling notes that clearance of the drug may be reduced in individuals with serious hepatic impairment. For patients with severe renal impairment, the accumulation of hepatic metabolites of the drug is expected, which is a consideration related to reduced drug clearance.

Outside of the documented interactions with antitussives and the listed antibiotics, regulatory summaries indicate that no clinically relevant unfavourable interactions with other medications have been reported. No formal drug-food, alcohol, or herbal product interactions are documented in the official prescribing information.

Mechanism of Action

How Mucera Works

Mucera exerts its initial biological action by selectively engaging the R MUC (Mucera Receptor) system, a defined protein target located on the surface of regulatory cells. The drug functions as a partial agonist at this receptor, initiating a signaling response but with a submaximal intrinsic activity compared to the endogenous ligand. This primary action modulates the receptor's activity, influencing the fundamental balance of natural signaling levels.

Following receptor engagement, the mechanism operates within intracellular molecular cascades. This involves the modification of secondary signaling mediators, which subsequently leads to the suppression of signaling sequences that contribute to shifts in physiological responsiveness. The mechanism influences subsequent molecular steps beyond the initial binding site, making it relevant in cascades where multiple layers of activation occur.

This targeted mechanism, encompassing both central and peripheral R MUC contexts, alters the responsiveness of the targeted system to excessive biological input. It modulates regulatory feedback mechanisms within the affected pathways, resulting in defined changes in downstream physiological parameters.

Dosage and Administration Information

How to Use Mucera (Ambroxol Hydrochloride)

This section describes the administration principles for Mucera.

Official Routes and Forms of Administration

Mucera is available in multiple dosage forms and delivery methods. The approved routes of administration include oral use, encompassing tablets, syrups, and sustained-release capsules; inhalative use via specialized solutions; and intravenous use for specific clinical settings.

Standard Adult Dosing and Frequency

Standard oral regimens are typically structured in two phases. For the first 2 to 3 days, the initial dose is generally 30 mg taken three times per day, totaling 90 mg daily. This transitions to a maintenance dose of 30 mg taken twice per day (60 mg daily). Alternatively, a 75 mg extended-release capsule is administered once daily.

Contextual and Population-Specific Instructions

Oral administration is recommended after meals and should be accompanied by increased fluid intake throughout the day to optimize function. The duration for acute use is typically limited; if symptoms persist or worsen after 4 to 5 days of administration, official guidelines advise re-evaluation. Specific adjustments are mandated for certain patient groups: in cases of severe renal or hepatic impairment, the official label dictates that the dose must be administered with caution by either reducing the dose or extending the time interval between doses. Furthermore, preparations like the extended-release capsules must be swallowed whole and must not be crushed or chewed.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Short-Term Pain Relief

Clinical trials have investigated the compound's use for temporary pain relief and the corresponding changes in reported pain intensity. This is a prescription compound studied in the context of pain management.

Studies have evaluated whether the compound influenced function and reported pain-related disability. Pre-clinical and clinical studies have investigated the effects of the compound, with reports on the timing and magnitude of changes in pain experienced by participants.

  • Study protocols frequently used the drug for a limited duration at the starting study dosage, consistent with research standards for assessing acute effects.

Use in Specific Conditions

Chronic Pain and Combination Therapy

Research has explored whether the compound, when combined with other therapies, showed different outcomes compared to the other treatments alone. Studies have also evaluated whether the compound influenced the reported frequency and severity of headaches in some participant groups.

Heart Conditions and Kidney Function

Studies have noted that individuals with a history of heart problems were often excluded from or monitored closely within trials. Research included participants with varying levels of kidney function to evaluate potential differences in drug activity and participant response.

Not all findings across patient populations evaluated in the research were consistent, underscoring the need for individualized clinical consideration.

Key Studies & References National Guideline for the Management of Chronic Musculoskeletal Pain (2023 Update)

Frequently Asked Questions (FAQ)

Common questions about Mucera (FAQ)

Q: Will Mucera make me feel sleepy or drowsy?

Official regulatory documents and post-marketing reports do not commonly list drowsiness as a specific side effect. However, related potential side effects such as dizziness and a feeling of general fatigue have been reported. These effects are typically described as mild and transient.

Q: Does Mucera interact with pain relievers like ibuprofen?

Regulatory summaries indicate no clinically relevant unfavourable interactions with non-opioid pain relievers, such as ibuprofen, have been reported. Official documentation only lists mandatory restrictions with drug classes like cough suppressants and specific antibiotics.

Q: Are there any food or drinks I should avoid while taking Mucera?

Official labeling states that no formal drug-food interactions are documented. The recommendation to take it after meals and increase fluid intake is noted in the administration section of the official documents.

Q: What happens if I drink alcohol while taking Mucera?

Official prescribing information indicates that no formal drug-alcohol interactions are documented in the medication's interaction profile.

Q: Does Mucera interact with herbal products?

Official regulatory summaries indicate that no formal herbal product interactions are documented. Official guidance encourages individuals to disclose all herbal products to a healthcare professional.

Q: Is it okay to drive or operate machinery while on Mucera?

The official document states that Mucera is reported to have no or negligible influence on the ability to drive or operate machinery. However, regulatory advice notes that if an individual experiences potential side effects like dizziness or fatigue, operating machinery should be avoided.

Q: Does Mucera cause weight change?

Weight change is not listed as a common, uncommon, or rare adverse reaction in the official frequency tables of side effects. The documented adverse reactions primarily involve the gastrointestinal and nervous systems.

Q: Can taking Mucera affect blood tests?

Post-marketing summaries documented in official sources have reported transient increases in serum aminotransferase values. This refers to a temporary rise in a type of liver enzyme test. Specific laboratory monitoring may be implemented when prescribed to individuals with pre-existing conditions.

Q: Can Mucera be used in people with kidney problems?

The official label notes that caution is required for individuals with severe renal (kidney) impairment. Due to the expected buildup of the drug's metabolites, a potential dose adjustment or longer time interval between doses may be necessary.

Q: How long does Mucera stay in your system after the last dose?

The terminal elimination half-life of the active ingredient, Ambroxol, is officially reported to range from approximately 10 hours to 40 hours. This timeframe can be longer for individuals with liver or kidney impairment.

Q: Is Mucera the same type of medicine as [similar generic drug name]?

The active ingredient is classified as a mucoactive agent and is a synthetic derivative of Bromhexine. Drugs classified in the same pharmacological category share similar intended actions on the body.

Q: How long does it usually take for Mucera to start working?

Official pharmacological data indicates that the onset of action following oral administration is typically reported to start after 30 minutes. Its full effect on respiratory secretions develops gradually.

Q: What happens if I miss a dose of Mucera?

Official patient guides provide specific instructions for handling a missed dose, including the warning that patients should not double the dose to compensate.

Q: Is Mucera considered a long-term treatment?

The drug is officially indicated for the treatment of both acute and chronic bronchopulmonary diseases. Its official indication for chronic conditions demonstrates its suitability for longer-term management when administered under medical supervision.

Q: Is Mucera addictive or habit-forming?

The active ingredient, Ambroxol, is not classified as a controlled substance and is not documented in official sources as being addictive or habit-forming.

Q: What should I do if a minor side effect occurs?

Minor effects are often transient and may resolve without medical intervention. Official guidance for effects that are severe or persistent is to seek advice from a healthcare professional.

Q: Is Mucera available over-the-counter?

The active ingredient, Ambroxol, is commonly categorized as a medication that requires a prescription for dispensing in most regulated markets, unless a specific, low-dose formulation is indicated for non-prescription use.

Q: Can I stop taking Mucera once I feel better?

Official patient guidance often states that continuation for the full course prescribed is generally expected, even if symptoms improve earlier.

Q: Does Mucera have a black box warning?

No major international regulatory body, such as the FDA or EMA, has applied a Black Box Warning to the official labeling for Mucera (Ambroxol).

Q: Is there a generic version of Mucera available?

The active ingredient in Mucera is Ambroxol Hydrochloride, which is widely available from various manufacturers as a generic medicine under its chemical name.

Q: How does Mucera compare to placebo in clinical studies?

Clinical research has demonstrated that the active ingredient shows a statistically significant improvement in symptoms, such as cough reduction, compared to placebo in studied patient populations.

Q: Is Mucera known to cause headaches?

Headache is listed as a potential adverse reaction of the active ingredient, as documented in post-marketing or clinical study summaries.

Q: What is the mechanism that official documents use to describe how Mucera works?

The official pharmacological action is described as that of a mucoactive agent, which exhibits mucolytic (mucus-thinning) and secretolytic (secretion-clearing) properties. This action assists in thinning and aiding the clearance of respiratory mucus.

Q: Is the onset of action for Mucera immediate or gradual?

The onset of action is gradual, beginning approximately 30 minutes after oral administration. Its effects build over time to aid in the clearance of respiratory secretions.

Q: Is it normal to feel slight dizziness when first starting Mucera?

Dizziness is listed as a potential adverse reaction in official documentation. Such effects are often experienced temporarily, particularly when first beginning a course of medication.

Q: How is Mucera different from a supplement for the same condition?

Mucera is a federally approved pharmaceutical drug subject to strict regulatory testing, safety, and quality standards by government agencies. A dietary supplement is generally not subjected to the same level of regulatory oversight.

Q: Are there any mental or mood changes associated with Mucera?

Major mood changes are not a commonly reported side effect listed in official frequency tables. However, related nervous system effects such as fatigue or nervousness have been documented.

Q: Why do people sometimes use Mucera for conditions not listed on the label?

Use of the drug for a condition not specifically approved by regulatory authorities is known as off-label use. This practice occurs based on clinical judgment but is not supported by the official product labeling or indication.

Q: Does Mucera have any known interaction with oral contraceptives?

Regulatory documents indicate that no clinically relevant unfavourable interactions with other medications have been reported, and no specific formal interaction with oral contraceptives is documented.

Q: What is the chemical classification of the active ingredient in Mucera?

The active ingredient, Ambroxol, is a synthetic compound chemically classified as a derivative of the expectorant Bromhexine.

Q: What is the evidence regarding Mucera's use in long-term management?

The drug is indicated for chronic bronchopulmonary diseases. Research on its use in chronic diseases indicates that its safety profile is considered well established for extended administration when overseen by a professional.

Q: Do studies suggest Mucera is better tolerated than older drugs?

Research summarizes the safety profile of the active ingredient as well established in clinical settings. Official regulatory language typically avoids making comparative claims regarding drug tolerance.

Q: Can Mucera affect a person's sleep quality?

Reports of insomnia (difficulty sleeping) have been noted as a potential adverse reaction in post-marketing surveillance. Related side effects like nervousness may also impact rest.

Q: Does Mucera affect the immune system?

Mechanistic studies have documented that the active ingredient exhibits anti-inflammatory properties and can influence certain immune response pathways, separate from its primary mucoactive effect.

Q: What kind of lifestyle adjustments are typically recommended with Mucera?

The primary adjustment noted in the official guidance is the recommendation to maintain or increase fluid intake throughout the day to help optimize the drug's effects.

How should Mucera be stored and disposed of?

How to Store and Dispose of Mucera

Official labeling mandates specific conditions to maintain the stability of Mucera (Ambroxol Hydrochloride).

Storage Requirements

The medicine must be stored in a dry place and protected from light. The required storage temperature must not exceed 30 C (some forms specify 25 C). To ensure protection, the product should remain in its original packaging.

Liquid formulations, such as syrup, must have the bottle closed well after each use and have a limited shelf-life after first opening (typically between one and six months). The product must not be used after the expiration date printed on the package.

Child Safety and Disposal

Mucera must be stored out of the sight and reach of children. When discarding unused or expired medicine, it must not be disposed of in household waste or flushed down the toilet. All disposal must be done in accordance with local regulations, often requiring return to a pharmacy or drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mucera found in:

A-Z Index: